According to a recent LinkedIn post from Circular Genomics, the company is adding Henrik Zetterberg, M.D., Ph.D., to its Scientific Advisory Board. The post describes Zetterberg as a professor of neurochemistry affiliated with the University of Gothenburg, the University of Wisconsin–Madison, and University College London, and a global leader in fluid biomarkers for neurodegenerative diseases.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The post suggests that Zetterberg’s expertise is expected to support Circular Genomics’ work on circular RNA (circRNA) biomarker technology aimed at making brain disorders more measurable. It specifically highlights efforts around blood-based assays for Alzheimer’s disease diagnosis and risk prediction, indicating a strategic focus on noninvasive diagnostic tools in neurology.
For investors, this advisory board addition may signal an effort to strengthen the company’s scientific credibility and translational pathway in a competitive neurodegeneration diagnostics market. Association with a recognized biomarker expert could help Circular Genomics in future partnerships, validation studies, and potential regulatory or commercial discussions, though the post does not disclose any timelines or financial details.